NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

$172.91

-6.05 (-3.38%)

(As of 10/3/2023 ET)

Compare

Today's Range: $172.51
▼
$179.77
50-Day Range: $170.77
▼
$211.65
52-Week Range: $168.65
▼
$242.97

Volume: 642,295 shs
Average Volume: 718,341 shs
Market Capitalization: $21.61 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $246.20

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.76 Rating Score
Upside/Downside: 42.4% Upside
$246.20 Price Target
Short Interest: Healthy
4.12% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.52
Upright™ Environmental Score
News Sentiment: 0.85
Based on 6 Articles This Week
Insider Trading: Selling Shares
$2.81 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.79) to ($3.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

88th out of 966 stocks

Pharmaceutical Preparations Industry

21st out of 442 stocks

4.4

Analyst's Opinion

Consensus Rating
Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $246.20, Alnylam Pharmaceuticals has a forecasted upside of 42.4% from its current price of $172.91.
Amount of Analyst Coverage
Alnylam Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.12% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Alnylam Pharmaceuticals has recently decreased by 2.83%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Alnylam Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alnylam Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alnylam Pharmaceuticals is -1.52.

2.7

News and Social Media Coverage

News Sentiment
Alnylam Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Alnylam Pharmaceuticals this week, compared to 7 articles on an average week.
Search Interest
15 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,806,347.00 in company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.
Percentage Held by Institutions
93.98% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.79) to ($3.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alnylam Pharmaceuticals is -20.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alnylam Pharmaceuticals is -20.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Price History

30 days | 90 days | 365 days | Advanced Chart

ALNY Stock News Headlines

September 25, 2023 | marketbeat.com

Argenx's 28% Surge & Promising Product Propel Investor Confidence (ALNY)

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

September 7, 2023 | marketbeat.com

3 Stocks to Buy For the COVID Resurgence (ALNY)

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

October 2, 2023 | news.yahoo.com

US FDA approves Novo Nordisk's therapy for rare genetic condition

September 30, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated at Raymond James

September 29, 2023 | msn.com

Raymond James Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Outperform Recommendation

September 26, 2023 | markets.businessinsider.com

Positive Clinical Trial Updates Boost Inozyme Pharma’s Buy Rating: Efficacy of INZ-701 in ENNP1 and ABCC6 Deficiencies

September 15, 2023 | msn.com

Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

September 15, 2023 | msn.com

Alnylam stock falls after FDA panel questions drug's effectiveness

September 14, 2023 | msn.com

Alnylam’s RNA interference drug wins favour of FDA AdCom

September 14, 2023 | markets.businessinsider.com

Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects

September 13, 2023 | marketwatch.com

Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA

September 13, 2023 | markets.businessinsider.com

Alnylam Pharmaceuticals: FDA Committee To Review SNDA For Patisiran; Trading Halted

September 12, 2023 | markets.businessinsider.com

What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

September 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and ADC Therapeutics (ADCT)

September 11, 2023 | benzinga.com

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today

September 11, 2023 | bloomberg.com

FDA Casts Doubt on Alnylam Drug Trial Results for Expanded Usage

September 9, 2023 | seekingalpha.com

Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility

September 9, 2023 | reuters.com

Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial

September 8, 2023 | bizjournals.com

BBJ honors corporate philanthropy leaders at annual event

September 8, 2023 | finance.yahoo.com

Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More

September 8, 2023 | markets.businessinsider.com

Citi Remains a Buy on Ionis Pharmaceuticals (IONS)

September 7, 2023 | bizjournals.com

Alnylam supports Cambridge-area addiction recovery program

September 7, 2023 | news.yahoo.com

Alnylam hypertension drug meets main goal in mid-stage study

September 7, 2023 | markets.businessinsider.com

Alnylam: KARDIA-1 Phase 2 Dose-Ranging Study Of Zilebesiran Meets Primary Endpoint

September 7, 2023 | finance.yahoo.com

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

See More Headlines

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings: 8/03/2023
Today: 10/04/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ALNY
CUSIP: 02043Q10
CIK: 1178670
Web: www.alnylam.com
Phone: (617) 551-8200
Fax: 617-551-8101
Employees: 2,002
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $246.20
High Stock Price Forecast: $405.00
Low Stock Price Forecast: $143.00
Forecasted Upside/Downside: +42.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.76
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,131,160,000.00
Net Margins: -85.95%
Pretax Margin: -85.63%
Return on Equity: N/A
Return on Assets: -30.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.20
Quick Ratio: 3.07

Sales & Book Value

Annual Sales: $1.24 billion
Price / Sales: 17.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.29) per share
Price / Book: -134.04

Miscellaneous

Outstanding Shares: 125,001,000
Free Float: 123,251,000
Market Cap: $21.61 billion
Optionable: Optionable
Beta: 0.48

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Yvonne L. Greenstreet M.B.A. (Age 60)
MBA, MBChB, CEO & Director
Comp: $2.09M

Dr. Akshay K. Vaishnaw M.D. (Age 60)
Ph.D., Pres
Comp: $1.24M

Mr. Jeffrey V. Poulton M.B.A. (Age 55)
CFO & Exec. VP
Comp: $972.35k

Ms. Indrani M. Lall Franchini J.D. (Age 51)
Exec. VP, Chief Legal Officer & Sec.
Comp: $958.96k

Dr. Pushkal P. Garg M.D. (Age 55)
Chief Medical Officer and Exec. VP of Devel. & Medical Affairs
Comp: $1M

Mr. Timothy J. Maines
Chief Technical Operations & Quality Officer

Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
Sr. VP, Head of Research & Chief Scientific Officer

Ms. Christine Regan Lindenboom (Age 42)
Sr. VP of Investor Relations & Corp. Communications

Mr. Piyush Sharma J.D.
Chief Ethics & Compliance Officer

Mr. Mark Baglin
VP of Global Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.
What is Alnylam Pharmaceuticals' stock price forecast for 2023?: 21 Wall Street research analysts have issued 1 year price objectives for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $405.00. On average, they expect the company's stock price to reach $246.20 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.
How have ALNY shares performed in 2023?: Alnylam Pharmaceuticals' stock was trading at $237.65 on January 1st, 2023. Since then, ALNY stock has decreased by 27.2% and is now trading at $172.91.
View the best growth stocks for 2023 here.
When is Alnylam Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ALNY earnings forecast.
How were Alnylam Pharmaceuticals' earnings last quarter?: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($1.72) by $0.49. The biopharmaceutical company earned $318.75 million during the quarter, compared to the consensus estimate of $331.73 million.
What ETFs hold Alnylam Pharmaceuticals' stock?: ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH) and Principal Healthcare Innovators ETF (BTEC).
What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?: Alnylam Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.44 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?: 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alnylam Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).
What is Alnylam Pharmaceuticals' stock symbol?: Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How do I buy shares of Alnylam Pharmaceuticals?: Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alnylam Pharmaceuticals' stock price today?: One share of ALNY stock can currently be purchased for approximately $172.91.
How much money does Alnylam Pharmaceuticals make?: Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $21.61 billion and generates $1.24 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.61) on an earnings per share basis.
How many employees does Alnylam Pharmaceuticals have?: The company employs 2,002 workers across the globe.
How can I contact Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial